Top

Published in:

01-12-1997 | ORIGINAL ARTICLE

Active antitumor immunotherapy, with or without B7-mediated costimulation, increases tumor progression in an immunogenic murine T cell lymphoma model

Authors: G. Raes, J. Van Ginderachter, Yuan Qing Liu, L. Brys, Kristiaan Thielemans, Patrick De Baetselier, Anja Geldhof

Published in: Cancer Immunology, Immunotherapy | Issue 5/1997

Title: Active antitumor immunotherapy, with or without B7-mediated costimulation, increases tumor progression in an immunogenic murine T cell lymphoma model
Authors: G. Raes
J. Van Ginderachter
Yuan Qing Liu
L. Brys
Kristiaan Thielemans
Patrick De Baetselier
Anja Geldhof
Publication date: 01-12-1997
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 5/1997
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s002620050441

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Please log in to get access to this content

Other articles of this Issue 5/1997

Multidimensional flow-cytometric analysis of dendritic cells in peripheral blood of normal donors and cancer patients

Induction by DNA immunization of a protective antitumor cytotoxic T lymphocyte response against a minimal-epitope-expressing tumor

Early-appearing tumor-infiltrating natural killer cells play an important role in the nitric oxide production of tumor-associated macrophages through their interferon production

The significance of an increase in soluble interleukin-2 receptor level in colorectal cancer and its biological regulating role in the physiological switching of the immune response cytokine network from TH1 to TH2 and back

Co-expression of immunogenic determinants by the same cellular immunogen is required for the optimum immunotherapeutic benefit in mice with melanoma

Phase I trial of adoptive immunotherapy of cancer patients using monocyte-derived macrophages activated with interferon γ and lipopolysaccharide

Keynote webinar | Spotlight on antibody–drug conjugates in cancer